ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates.

John Dombrosky is taking over the helm of the newly founded Oerth Bio, a targeted protein degradation joint venture launched by Bayer and US biotech Arvinas.

Licencing bluebird bio’s Inc know-how and technology in one-time gene therapies, Novo Nordisk A/S tries to get a foothold in the emerging haemophilia A gene therapy market.

It is a brand-new role at Bournemouth-based Life Sciences company Solentim: Mark Stockdale will join the global leader in cell line development instrumentation as as “Amalgamator of Business and Biology”.

Evotec SE has expanded its drug discovery customer base with US women’s health specialist Celmatix Inc.

Biom’up SA, specialising in surgical hemostasis, appointed Patrice Ferrand as their new CEO. Ferrand replaces Jan Ohrstrom, who was appointed CEO since May and remains Chairman of the Board.

QIAGEN and Illumina join forces in the next-gen sequencing-based IVD testing and companion diagnostics market announcing a 15-year collaboration. 

Many users in research labs like to store their assay components such as assay antibodies, conjugates, antigens, calibrators or coated ELISA plates for a while without losing functionality.

German researchers have determined the mechanism of a ADEPs, a novel class of antibiotics, allowing for pharmacological optimisation.

A new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.